Orexin Antagonist and Psychedelic Drug Combination for Neuropsychiatric Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropsychiatric disorders, particularly depression and anxiety, often fail to effectively address sleep disturbances and cognitive enhancement, and existing dual orexin receptor antagonists may not be sufficient for major depressive disorder (MDD) or have limitations in abuse liability.
Innovation Solution
A method involving the administration of a combination of an orexin receptor antagonist and a serotonin receptor agonist or an NMDA receptor antagonist, particularly at low to moderate doses, to promote sleep and enhance cognitive and emotional processing, incorporating behavioral approaches like dream incubation to facilitate memory consolidation and reduce the risk of misuse.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dual orexin receptor antagonists are used to treat insomnia, then sleep quality is improved, but they are insufficient for treating major depressive disorder and have limitations in abuse liability
Solution Approach 1:
The patent combines dual orexin receptor antagonists with psychedelic-related drugs (serotonin receptor agonists or NMDA receptor antagonists) into a single treatment regimen. This merging of two distinct therapeutic approaches allows the composition to address both insomnia and neuropsychiatric conditions like MDD, thereby expanding treatment scope while maintaining sleep quality improvements
Solution Approach 2:
The invention creates a composite pharmaceutical composition containing both orexin receptor antagonist and psychedelic-related drug components. This composite formulation integrates the sleep-promoting effects of the antagonist with the mood-enhancing and cognitive benefits of the psychedelic-related substance, providing a multi-functional treatment that addresses both sleep disturbances and neuropsychiatric symptoms
2Reliability
If psychedelic drugs are used to enhance mood and cognition, then emotional processing is improved, but sleep disturbances occur and abuse liability increases
Solution Approach 1:
The orexin receptor antagonist is administered to preemptively counteract the sleep-disturbing effects of psychedelic drugs. By blocking orexin receptors beforehand, the composition prevents the arousal and insomnia that typically accompany psychedelic use, allowing mood and cognitive benefits to occur without the harmful sleep disturbances
Solution Approach 2:
The orexin receptor antagonist acts as an intermediary substance that mediates between the mood-enhancing psychedelic component and the sleep architecture. It translates the activating effects of the psychedelic into a form that does not disrupt sleep, bridging the gap between emotional processing enhancement and sleep maintenance
3Use of energy by moving object
If high doses of psychedelic drugs are taken for recreational use, then intense effects are achieved, but the risk of abuse and misuse increases
Solution Approach 1:
The invention changes the dosing parameters and administration regimen of the psychedelic-related drug when combined with the orexin receptor antagonist. This parameter modification allows for effective mood and cognitive enhancement at doses that have reduced abuse potential, as the combined composition produces therapeutic effects without the intense euphoric experiences that drive recreational misuse
Data Source
AI summary
The disclosure provides, in part, a method of treating a neuropsychiatric disorder in a patient in need thereof, comprising administering to the patient an effective amount of an orexin receptor antagonist and further comprising administering to the patient an effective amount of a serotonin 2A receptor agonist or an NMDA receptor antagonist.